The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.
The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.
Rahman
Shafiqur
S
Center for Drug Abuse Research Translation, University of Kentucky, Lexington, KY 40506, USA. Shafiqur.Rahman@sdstate.edu
Neugebauer
Nichole M
NM
Zhang
Zhenfa
Z
Crooks
Peter A
PA
Dwoskin
Linda P
LP
Bardo
Michael T
MT
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D008297:Male; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D010847:Picolines / Q000008:administration & dosage / Q000494:pharmacology*; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
C513964:N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D010847:Picolines; D015102:3,4-Dihydroxyphenylacetic Acid; D009538:Nicotine; D004298:Dopamine